Symphogen is leading the development of antibody mixture therapeutics to improve the treatment of cancer.
Symphogen's growing pipeline of cancer programs reflects a new approach to fighting cancer with unique mechanisms based on multiple simultaneous attacks on tumors. The result is improved efficacy and the potential to reduce the development of drug resistance.
- Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line
- Sym004 Advances into Two New Clinical Trials and Receives Milestone Payments
- Symphogen to Report Preliminary Safety and Exploratory Efficacy Data from a Phase 1 Study of Sym004, Anti-EGFR Monoclonal Antibody Mixture at ASCO
- More news